ID   TAOK2_RAT               Reviewed;        1235 AA.
AC   Q9JLS3; A6BM05;
DT   25-OCT-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   24-JUN-2015, entry version 112.
DE   RecName: Full=Serine/threonine-protein kinase TAO2;
DE            EC=2.7.11.1;
DE   AltName: Full=Thousand and one amino acid protein 2;
GN   Name=Taok2; Synonyms=Tao2;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND INTERACTION WITH
RP   MAP2K3 AND MAP2K6.
RC   TISSUE=Brain;
RX   PubMed=10497253; DOI=10.1074/jbc.274.40.28803;
RA   Chen Z., Hutchison M., Cobb M.H.;
RT   "Isolation of the protein kinase TAO2 and identification of its
RT   mitogen-activated protein kinase/extracellular signal-regulated kinase
RT   kinase binding domain.";
RL   J. Biol. Chem. 274:28803-28807(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, INTERACTION WITH
RP   PCDH8, SUBCELLULAR LOCATION, MUTAGENESIS OF LYS-57, AND
RP   PHOSPHORYLATION AT SER-1038 (ISOFORM 2).
RX   PubMed=17988630; DOI=10.1016/j.neuron.2007.08.020;
RA   Yasuda S., Tanaka H., Sugiura H., Okamura K., Sakaguchi T., Tran U.,
RA   Takemiya T., Mizoguchi A., Yagita Y., Sakurai T., De Robertis E.M.,
RA   Yamagata K.;
RT   "Activity-induced protocadherin arcadlin regulates dendritic spine
RT   number by triggering N-cadherin endocytosis via TAO2beta and p38 MAP
RT   kinases.";
RL   Neuron 56:456-471(2007).
RN   [3]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 1-320, AND PHOSPHORYLATION AT
RP   SER-181.
RX   PubMed=15458637; DOI=10.1016/j.str.2004.07.021;
RA   Zhou T., Raman M., Gao Y., Earnest S., Chen Z., Machius M., Cobb M.H.,
RA   Goldsmith E.J.;
RT   "Crystal structure of the TAO2 kinase domain: activation and
RT   specificity of a Ste20p MAP3K.";
RL   Structure 12:1891-1900(2004).
RN   [4]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 1-320 IN COMPLEX WITH
RP   STAUROSPORINE, AND ENZYME REGULATION.
RX   PubMed=16761096; DOI=10.1111/j.1745-7270.2006.00173.x;
RA   Zhou T.J., Sun L.G., Gao Y., Goldsmith E.J.;
RT   "Crystal structure of the MAP3K TAO2 kinase domain bound by an
RT   inhibitor staurosporine.";
RL   Acta Biochim. Biophys. Sin. 38:385-392(2006).
CC   -!- FUNCTION: Serine/threonine-protein kinase involved in different
CC       processes such as membrane blebbing and apoptotic bodies formation
CC       DNA damage response and MAPK14/p38 MAPK stress-activated MAPK
CC       cascade. Phosphorylates itself, MBP, activated MAPK8, MAP2K3,
CC       MAP2K6 and tubulins. Activates the MAPK14/p38 MAPK signaling
CC       pathway through the specific activation and phosphorylation of the
CC       upstream MAP2K3 and MAP2K6 kinases. In response to DNA damage,
CC       involved in the G2/M transition DNA damage checkpoint by
CC       activating the p38/MAPK14 stress-activated MAPK cascade, probably
CC       by mediating phosphorylation of upstream MAP2K3 and MAP2K6
CC       kinases. May affect microtubule organization and stability. May
CC       play a role in the osmotic stress-MAPK8 pathway. Prevents MAP3K7-
CC       mediated activation of CHUK, and thus NF-kappa-B activation.
CC       Isoform 2, but not isoform 1, is required for PCDH8 endocytosis.
CC       Following homophilic interactions between PCDH8 extracellular
CC       domains, isoform 2 phosphorylates and activates MAPK14/p38 MAPK
CC       which in turn phosphorylates isoform 2. This process leads to
CC       PCDH8 endocytosis and CDH2 cointernalization. Both isoforms are
CC       involved in MAPK14/p38 MAPK activation.
CC       {ECO:0000269|PubMed:10497253, ECO:0000269|PubMed:17988630}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- ENZYME REGULATION: Moderately inhibited by staurosporine, a broad-
CC       range protein kinase inhibitor. {ECO:0000269|PubMed:16761096}.
CC   -!- SUBUNIT: Self-associates. Interacts with MAP2K3 and MAP2K6.
CC       Interacts with tubulins. Interacts with MAP3K7 and interfers with
CC       MAP3K7-binding to CHUK and thus prevents NF-kappa-B activation (By
CC       similarity). Isoform 2 interacts with PCDH8; this complex may also
CC       include CDH2. {ECO:0000250, ECO:0000269|PubMed:10497253,
CC       ECO:0000269|PubMed:16761096, ECO:0000269|PubMed:17988630}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasmic vesicle membrane {ECO:0000250};
CC       Multi-pass membrane protein {ECO:0000250}. Cytoplasm, cytoskeleton
CC       {ECO:0000250}. Note=Found to be perinuclear and localized to
CC       vesicular compartment. {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Cell projection, dendrite.
CC       Note=In dendrites, colocalizes with PCDH8.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=TAO2-alpha;
CC         IsoId=Q9JLS3-1; Sequence=Displayed;
CC       Name=2; Synonyms=TAO2-beta;
CC         IsoId=Q9JLS3-2; Sequence=VSP_040545, VSP_040546, VSP_040547;
CC         Note=Contains a phosphoserine at position 1038.;
CC   -!- PTM: Autophosphorylated. Phosphorylated by ATM (By similarity).
CC       {ECO:0000250}.
CC   -!- PTM: Isoform 2: Phosphorylated on Ser-1038 by MAPK14. This
CC       phosphorylation is required PCDH8 for endocytosis.
CC       {ECO:0000269|PubMed:15458637}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr
CC       protein kinase family. STE20 subfamily. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF140556; AAD39480.2; -; mRNA.
DR   EMBL; AB290408; BAF64457.1; -; mRNA.
DR   RefSeq; NP_073193.1; NM_022702.1. [Q9JLS3-1]
DR   UniGene; Rn.9575; -.
DR   PDB; 1U5Q; X-ray; 2.10 A; A/B=1-320.
DR   PDB; 1U5R; X-ray; 2.10 A; A/B=1-320.
DR   PDB; 2GCD; X-ray; 2.55 A; A/B=12-320.
DR   PDBsum; 1U5Q; -.
DR   PDBsum; 1U5R; -.
DR   PDBsum; 2GCD; -.
DR   ProteinModelPortal; Q9JLS3; -.
DR   SMR; Q9JLS3; 12-320.
DR   IntAct; Q9JLS3; 1.
DR   STRING; 10116.ENSRNOP00000061854; -.
DR   PhosphoSite; Q9JLS3; -.
DR   PaxDb; Q9JLS3; -.
DR   PRIDE; Q9JLS3; -.
DR   GeneID; 64666; -.
DR   KEGG; rno:64666; -.
DR   UCSC; RGD:621590; rat. [Q9JLS3-1]
DR   CTD; 9344; -.
DR   RGD; 621590; Taok2.
DR   eggNOG; COG0515; -.
DR   HOGENOM; HOG000236358; -.
DR   HOVERGEN; HBG088996; -.
DR   InParanoid; Q9JLS3; -.
DR   KO; K04429; -.
DR   PhylomeDB; Q9JLS3; -.
DR   EvolutionaryTrace; Q9JLS3; -.
DR   NextBio; 613649; -.
DR   PRO; PR:Q9JLS3; -.
DR   Proteomes; UP000002494; Unplaced.
DR   Genevisible; Q9JLS3; RN.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0030659; C:cytoplasmic vesicle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005856; C:cytoskeleton; IEA:UniProtKB-SubCell.
DR   GO; GO:0030425; C:dendrite; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IDA:RGD.
DR   GO; GO:0004709; F:MAP kinase kinase kinase activity; IDA:RGD.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; ISS:UniProtKB.
DR   GO; GO:0000186; P:activation of MAPKK activity; IDA:GOC.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; ISS:UniProtKB.
DR   GO; GO:0031572; P:G2 DNA damage checkpoint; ISS:UniProtKB.
DR   GO; GO:0000165; P:MAPK cascade; IDA:RGD.
DR   GO; GO:0032874; P:positive regulation of stress-activated MAPK cascade; ISS:UniProtKB.
DR   GO; GO:0042981; P:regulation of apoptotic process; IBA:GO_Central.
DR   GO; GO:0007346; P:regulation of mitotic cell cycle; IBA:GO_Central.
DR   GO; GO:0051403; P:stress-activated MAPK cascade; ISS:UniProtKB.
DR   GO; GO:0031098; P:stress-activated protein kinase signaling cascade; IBA:GO_Central.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR002290; Ser/Thr_dual-sp_kinase.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell projection;
KW   Coiled coil; Complete proteome; Cytoplasm; Cytoplasmic vesicle;
KW   Cytoskeleton; Kinase; Magnesium; Membrane; Nucleotide-binding;
KW   Phosphoprotein; Reference proteome; Serine/threonine-protein kinase;
KW   Transferase; Transmembrane; Transmembrane helix.
FT   CHAIN         1   1235       Serine/threonine-protein kinase TAO2.
FT                                /FTId=PRO_0000086735.
FT   TRANSMEM    967    987       Helical. {ECO:0000255}.
FT   TRANSMEM    989   1009       Helical. {ECO:0000255}.
FT   TRANSMEM   1014   1034       Helical. {ECO:0000255}.
FT   TRANSMEM   1040   1060       Helical. {ECO:0000255}.
FT   TRANSMEM   1170   1190       Helical. {ECO:0000255}.
FT   DOMAIN       28    281       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND      34     42       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   COILED      488    523       {ECO:0000255}.
FT   COILED      576    603       {ECO:0000255}.
FT   COILED      683    715       {ECO:0000255}.
FT   COMPBIAS    330    336       Poly-Glu.
FT   COMPBIAS    347    370       Ser-rich.
FT   COMPBIAS    378    408       Glu-rich.
FT   COMPBIAS    450    455       Poly-Ser.
FT   COMPBIAS    791    794       Poly-Glu.
FT   COMPBIAS    900    908       Poly-Glu.
FT   COMPBIAS    945   1062       Leu-rich.
FT   ACT_SITE    151    151       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING      57     57       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   BINDING     106    106       Staurosporine inhibitor.
FT                                {ECO:0000269|PubMed:16761096}.
FT   BINDING     108    108       Staurosporine inhibitor.
FT                                {ECO:0000269|PubMed:16761096}.
FT   BINDING     155    155       Staurosporine inhibitor; via carbonyl
FT                                oxygen. {ECO:0000269|PubMed:16761096}.
FT   MOD_RES       9      9       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9UL54}.
FT   MOD_RES     181    181       Phosphoserine.
FT                                {ECO:0000269|PubMed:15458637}.
FT   MOD_RES     416    416       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9UL54}.
FT   MOD_RES     777    777       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9UL54}.
FT   MOD_RES     825    825       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9UL54}.
FT   MOD_RES     827    827       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9UL54}.
FT   VAR_SEQ     333    333       E -> ELTPCSQ (in isoform 2).
FT                                {ECO:0000303|PubMed:17988630}.
FT                                /FTId=VSP_040545.
FT   VAR_SEQ     747   1050       VRAGQLPMGLPATGALGPLSTGTLSEEQPCSSGQEAILGQR
FT                                MLGEEEEAVPERMILGKEGTTLEPEEQRILGEEMGTFSSSP
FT                                QKHRSLVNEEDWDISKEMKESRVPSLASQERNIIGQEEAGA
FT                                WNLWEKEHGNLVDMEFKLGWVQGPVLTPVPEEEEEEEEEGG
FT                                APIGTPRDPGDGCPSPDIPPEPPPSHLRQYPASQLPGFLSH
FT                                GLLTGLSFAVGSSSGLLPLLLLLLLPLLAAQGGGGLQAALL
FT                                ALEVGLVGLGASYLFLCTALHLPPSLFLLLAQGTALGAVLS
FT                                LSWRRGLMGVPLGLGAA -> SKELQIKKQFQETCKIQTRQ
FT                                YKALRAHLLETTPKAQHKSLVKRLKEEQTRKLAILAEQYDQ
FT                                SISEMLSSQALRLDETQEAEFQALRQRSNRNWSSLMLTRAR
FT                                SKIRTESQHERELRELEQRVALRRALLEQRVEEELLALQTG
FT                                RSERIRSLLERQAREIEAFDAESMRLGFSSMALGGIPAEAA
FT                                AQGYPAPPPAPAWPSRPVPRSGAHWSHGPPPPGMPPPAWRX
FT                                PALLAPPGPPNWLGPPTQSGTPSGGALLLLRNSPQPLKRAA
FT                                SGGSSGENVGPPAAVPGPLSRSTSVASHILNGSSHFYS
FT                                (in isoform 2).
FT                                {ECO:0000303|PubMed:17988630}.
FT                                /FTId=VSP_040546.
FT   VAR_SEQ    1051   1235       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:17988630}.
FT                                /FTId=VSP_040547.
FT   MUTAGEN      57     57       K->A: Loss of activity. Loss of MAPK14
FT                                phosphorylation and of PCDH8
FT                                internalization.
FT                                {ECO:0000269|PubMed:17988630}.
FT   CONFLICT    434    434       P -> L (in Ref. 2; BAF64457).
FT                                {ECO:0000305}.
FT   HELIX        13     18       {ECO:0000244|PDB:1U5Q}.
FT   HELIX        24     27       {ECO:0000244|PDB:1U5Q}.
FT   STRAND       28     36       {ECO:0000244|PDB:1U5Q}.
FT   STRAND       38     47       {ECO:0000244|PDB:1U5Q}.
FT   TURN         48     51       {ECO:0000244|PDB:1U5Q}.
FT   STRAND       52     61       {ECO:0000244|PDB:1U5Q}.
FT   HELIX        66     82       {ECO:0000244|PDB:1U5Q}.
FT   STRAND       91     97       {ECO:0000244|PDB:1U5Q}.
FT   STRAND      100    106       {ECO:0000244|PDB:1U5Q}.
FT   STRAND      109    111       {ECO:0000244|PDB:1U5Q}.
FT   HELIX       112    119       {ECO:0000244|PDB:1U5Q}.
FT   HELIX       125    144       {ECO:0000244|PDB:1U5Q}.
FT   HELIX       154    156       {ECO:0000244|PDB:1U5Q}.
FT   STRAND      157    160       {ECO:0000244|PDB:1U5Q}.
FT   TURN        161    163       {ECO:0000244|PDB:1U5Q}.
FT   STRAND      164    167       {ECO:0000244|PDB:1U5Q}.
FT   STRAND      174    179       {ECO:0000244|PDB:1U5Q}.
FT   HELIX       186    188       {ECO:0000244|PDB:1U5Q}.
FT   HELIX       191    195       {ECO:0000244|PDB:1U5Q}.
FT   TURN        196    199       {ECO:0000244|PDB:2GCD}.
FT   HELIX       205    220       {ECO:0000244|PDB:1U5Q}.
FT   TURN        224    227       {ECO:0000244|PDB:1U5Q}.
FT   HELIX       230    239       {ECO:0000244|PDB:1U5Q}.
FT   HELIX       252    261       {ECO:0000244|PDB:1U5Q}.
FT   HELIX       266    268       {ECO:0000244|PDB:1U5Q}.
FT   HELIX       272    275       {ECO:0000244|PDB:1U5Q}.
FT   HELIX       279    282       {ECO:0000244|PDB:1U5Q}.
FT   HELIX       289    303       {ECO:0000244|PDB:1U5Q}.
FT   STRAND      304    306       {ECO:0000244|PDB:2GCD}.
FT   HELIX       307    309       {ECO:0000244|PDB:1U5Q}.
FT   HELIX       311    319       {ECO:0000244|PDB:1U5Q}.
SQ   SEQUENCE   1235 AA;  138751 MW;  426960D0812518AD CRC64;
     MPAGGRAGSL KDPDVAELFF KDDPEKLFSD LREIGHGSFG AVYFARDVRN SEVVAIKKMS
     YSGKQSNEKW QDIIKEVRFL QKLRHPNTIQ YRGCYLREHT AWLVMEYCLG SASDLLEVHK
     KPLQEVEIAA VTHGALQGLA YLHSHNMIHR DVKAGNILLS EPGLVKLGDF GSASIMAPAN
     SFVGTPYWMA PEVILAMDEG QYDGKVDVWS LGITCIELAE RKPPLFNMNA MSALYHIAQN
     ESPALQSGHW SEYFRNFVDS CLQKIPQDRP TSEVLLKHRF VLRERPPTVI MDLIQRTKDA
     VRELDNLQYR KMKKILFQEA PNGPGAEAPE EEEEAEPYMH RAGTLTSLES SHSVPSMSIS
     ASSQSSSVNS LADASDNEEE EEEEEEEEEE EEEEGPESRE MAMMQEGEHT VTSHSSIIHR
     LPGSDNLYDD PYQPEMTPGP LQPPAAPPTS TSSSSARRRA YCRNRDHFAT IRTASLVSRQ
     IQEHEQDSAL REQLSGYKRM RRQHQKQLLA LESRLRGERE EHSGRLQREL EAQRAGFGTE
     AEKLARRHQA IGEKEARAAQ AEERKFQQHI LGQQKKELAA LLEAQKRTYK LRKEQLKEEL
     QENPSTPKRE KAEWLLRQKE QLQQCQAEEE AGLLRRQRQY FELQCRQYKR KMLLARHSLD
     QDLLREDLNK KQTQKDLECA LLLRQHEATR ELELRQLQAV QRTRAELTRL QHQTELGNQL
     EYNKRREQEL RQKHAAQVRQ QPKSLKVRAG QLPMGLPATG ALGPLSTGTL SEEQPCSSGQ
     EAILGQRMLG EEEEAVPERM ILGKEGTTLE PEEQRILGEE MGTFSSSPQK HRSLVNEEDW
     DISKEMKESR VPSLASQERN IIGQEEAGAW NLWEKEHGNL VDMEFKLGWV QGPVLTPVPE
     EEEEEEEEGG APIGTPRDPG DGCPSPDIPP EPPPSHLRQY PASQLPGFLS HGLLTGLSFA
     VGSSSGLLPL LLLLLLPLLA AQGGGGLQAA LLALEVGLVG LGASYLFLCT ALHLPPSLFL
     LLAQGTALGA VLSLSWRRGL MGVPLGLGAA WLLAWPSLAL PLAAMAAGGK WVRQQGPQMR
     RGISRLWLRV LLRLSPMVFR ALQGCAAVGD RGLFALYPKT NKNGFRSRLP VPWPRQGNPR
     TTQHPLALLA RVWALCKGWN WRLARASHRL ASCLPPWAVH ILASWGLLKG ERPSRIPRLL
     PRSQRRLGLS ASRQLPPGTV AGRRSQTRRA LPPWR
//
